TECENTRIQ Market Summary

Key Factors Driving TECENTRIQ Growth

1. Broad, diversified oncology franchise across multiple tumor types: TECENTRIQ (atezolizumab), an anti-PD-L1 immune checkpoint inhibitor, has an established presence across NSCLC, extensive-stage SCLC, hepatocellular carcinoma (HCC), bladder/urothelial cancer, PD-L1-positive triple-negative breast cancer (TNBC), melanoma and alveolar soft part sarcoma (ASPS). This diversification reduces dependence on a single indication and provides multiple avenues for lifecycle management. FDA's current information confirms that the subcutaneous formulation covers the adult indications of IV atezolizumab, including NSCLC, SCLC, HCC, melanoma and ASPS.

2. Strong 2025 revenue base despite competitive pressure: Roche reported CHF 3.57 billion in TECENTRIQ sales in 2025, representing 3% growth at constant exchange rates versus CHF 3.64 billion in 2024. Importantly, this growth occurred despite declining US sales, demonstrating resilience from international markets. Roche specifically reported that growth was driven by the International region, notably China, while competitive pressure affected the US and Japan.

3. China and international-market expansion provide an important growth engine: In the first half of 2025, TECENTRIQ sales in the International region increased 13% at constant exchange rates, compared with a 6% decline in the US and 4% decline in Japan. Roche highlighted China as a major contributor to International growth. This geographic diversification is particularly important as mature markets face competition from other checkpoint inhibitors and changing treatment patterns.

4. Subcutaneous TECENTRIQ Hybreza can improve treatment convenience and utilization: FDA approved Tecentriq Hybreza in September 2024 as the first and, at approval, only subcutaneous PD-(L)1 cancer immunotherapy. The SC formulation can be administered in approximately 7 minutes, compared with roughly 30–60 minutes for IV infusion, while demonstrating safety and efficacy consistent with IV TECENTRIQ. Greater convenience can facilitate outpatient administration, improve patient and healthcare-provider experience, and potentially support continued use of the franchise in competitive treatment settings.

5. Expansion into earlier-stage disease could create additional revenue opportunities: Roche's lifecycle-development strategy is increasingly moving TECENTRIQ beyond advanced/metastatic disease. A particularly important opportunity is muscle-invasive bladder cancer (MIBC). In October 2025, Roche reported positive Phase III IMvigor011 results in a ctDNA-guided adjuvant setting: TECENTRIQ reduced the risk of death by 41% and the risk of disease recurrence or death by 36% versus placebo. If translated into regulatory approvals and clinical adoption, this biomarker-selected postoperative population could provide an additional growth avenue for TECENTRIQ.

TECENTRIQ Recent Developments

In April 2026, Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the approval of ZEPZELCA (lurbinectedin), in combination with Atezolizumab (TECENTRIQ), as a new first-line maintenance treatment option for adult patients in Australia and Singapore, who have been diagnosed with extensive-stage small cell lung cancer (ES-SCLC), an aggressive form of lung cancer. This follows the recent decision by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) to issue a positive opinion recommending the approval of ZEPZELCA in Europe.

In November 2025, KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapies, announced a clinical trial collaboration and supply agreement with Roche to evaluate VET3-TGI, a novel oncolytic immunotherapy developed using KaliVir’s proprietary Vaccinia Enhanced Template (VET) platform, in combination with Roche’s atezolizumab (TECENTRIQ).

“TECENTRIQ Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of TECENTRIQ for approved indication like Breast cancer, Liver cancer, Malignant melanoma, Non-small cell lung cancer, Small cell lung cancer, as well as potential indication like Fallopian tube cancer, Gastrointestinal cancer, Malignant-mesothelioma, Ovarian cancer, and Peritoneal cancer in the 7MM. A detailed picture of TECENTRIQ’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the TECENTRIQ for approved and potential indications. The TECENTRIQ market report provides insights about TECENTRIQ’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current TECENTRIQ performance, future market assessments inclusive of the TECENTRIQ market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of TECENTRIQ sales forecasts, along with factors driving its market.

TECENTRIQ Drug Summary

TECENTRIQ (Atezolizumab) is a humanized monoclonal antibody and immune checkpoint inhibitor developed by Genentech, a member of the Roche Group, that targets programmed death-ligand 1 (PD-L1). By binding to PD-L1, atezolizumab blocks its interaction with PD-1 and B7.1 receptors, thereby restoring T-cell activity and enhancing the immune system’s ability to recognize and attack cancer cells. TECENTRIQ is administered primarily through intravenous infusion and is approved for multiple cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and alveolar soft-part sarcoma (ASPS), with use varying by regulatory jurisdiction and treatment setting. It can be used as monotherapy or in combination with chemotherapy and other anticancer therapies, making it an important PD-L1-directed immunotherapy across both metastatic and selected earlier-stage cancers. The report provides TECENTRIQ’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the TECENTRIQ Market Report

The report provides insights into:

• A comprehensive product overview including the TECENTRIQ MoA, description, dosage and administration, research and development activities in approved indications like Breast cancer, Liver cancer, Malignant melanoma, Non-small cell lung cancer, Small cell lung cancer, as well as potential indication like Fallopian tube cancer, Gastrointestinal cancer, Malignant-mesothelioma, Ovarian cancer, and Peritoneal cancer.
• Elaborated details on TECENTRIQ regulatory milestones and other development activities have been provided in TECENTRIQ market report.
• The report also highlights TECENTRIQ‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The TECENTRIQ market report also covers the patents information, generic entry and impact on cost cut.
• The TECENTRIQ market report contains current and forecasted TECENTRIQ sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The TECENTRIQ market report also features the SWOT analysis with analyst views for TECENTRIQ in approved and potential indications.

Methodology

The TECENTRIQ market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TECENTRIQ Analytical Perspective by DelveInsight

• In-depth TECENTRIQ Market Assessment

This TECENTRIQ sales market forecast report provides a detailed market assessment of TECENTRIQ for approved indication like Breast cancer, Liver cancer, Malignant melanoma, Non-small cell lung cancer, Small cell lung cancer, as well as potential indication like Fallopian tube cancer, Gastrointestinal cancer, Malignant-mesothelioma, Ovarian cancer, and Peritoneal cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted TECENTRIQ sales data uptil 2034.

• TECENTRIQ Clinical Assessment

The TECENTRIQ market report provides the clinical trials information of TECENTRIQ for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

TECENTRIQ Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

TECENTRIQ Market Potential & Revenue Forecast

• Projected market size for the TECENTRIQ and its key indications
• Estimated TECENTRIQ sales potential (TECENTRIQ peak sales forecasts)
• TECENTRIQ Pricing strategies and reimbursement landscape

TECENTRIQ Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• TECENTRIQ Market positioning compared to existing treatments
• TECENTRIQ Strengths & weaknesses relative to competitors

TECENTRIQ Regulatory & Commercial Milestones

• TECENTRIQ Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

TECENTRIQ Clinical Differentiation

• TECENTRIQ Efficacy & safety advantages over existing drugs
• TECENTRIQ Unique selling points

TECENTRIQ Market Report Highlights

• In the coming years, the TECENTRIQ market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The TECENTRIQ companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TECENTRIQ’s dominance.
• Other emerging products for Breast cancer, Liver cancer, Malignant melanoma, Non-small cell lung cancer, Small cell lung cancer, as well as potential indication like Fallopian tube cancer, Gastrointestinal cancer, Malignant-mesothelioma, Ovarian cancer, and Peritoneal cancer are expected to give tough market competition to TECENTRIQ and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TECENTRIQ in approved and potential indications.
• Analyse TECENTRIQ cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted TECENTRIQ sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of TECENTRIQ in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of TECENTRIQ? How strong is TECENTRIQ’s clinical and commercial performance?
• What is TECENTRIQ’s clinical trial status in each individual indications such as Breast cancer, Liver cancer, Malignant melanoma, Non-small cell lung cancer, Small cell lung cancer, as well as potential indication like Fallopian tube cancer, Gastrointestinal cancer, Malignant-mesothelioma, Ovarian cancer, and Peritoneal cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TECENTRIQ Manufacturers?
• What are the key designations that have been granted to TECENTRIQ for approved and potential indications? How are they going to impact TECENTRIQ’s penetration in various geographies?
• What is the current and forecasted TECENTRIQ market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of TECENTRIQ in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to TECENTRIQ for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is TECENTRIQ? What is the duration of therapy and what are the geographical variations in cost per patient?